Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 141.00
Bid: 140.80
Ask: 141.40
Change: -0.20 (-0.14%)
Spread: 0.60 (0.426%)
Open: 143.40
High: 144.20
Low: 140.60
Prev. Close: 141.20
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Applications for Admission of Nil Paid Rights

3 Oct 2018 15:16

ELEMENTIS PLC - Applications for Admission of Nil Paid Rights

ELEMENTIS PLC - Applications for Admission of Nil Paid Rights

PR Newswire

London, October 3

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO ANY OF THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT IS NOT A PROSPECTUS BUT AN ADVERTISEMENT. INVESTORS SHOULD NOT SUBSCRIBE FOR THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT EXCEPT ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS.

FOR IMMEDIATE RELEASE

3 October 2018

ELEMENTIS PLC

Applications for Admission of Nil Paid Rights

Elementis plc ("Elementis" or the "Company") announces that, following the passing of the Resolution in connection with the acquisition of the entire issued share capital of Mondo Minerals Holding B.V. at the General Meeting earlier today, pursuant to the Rights Issue announced on 11 September 2018, applications have been made to the UK Listing Authority for 116,061,865 New Ordinary Shares (calculated on the basis of the number of Ordinary Shares in issue as at 6.00 p.m. on 1 October 2018, being the Record Date for entitlements under the Rights Issue) to be admitted to listing on the premium segment of the Official List of the UK Listing Authority and to be admitted, nil paid, to trading on the London Stock Exchange's main market for listed securities at 8.00 a.m. on 4 October 2018.

Capitalised terms used but not defined in this announcement have the meaning given to them in the Prospectus dated 11 September 2018.

Enquiries:

Elementis plcJames Curran, Investor Relations +44 (0) 207 067 2994

TulchanMartin Robinson +44 (0) 207 353 4200Sheebani Chothani

UBS (Joint Global Coordinator, Joint Bookrunner, Sole Corporate Broker and Sole Sponsor to Elementis)Rahul Luthra +44 (0) 207 567 8000Christopher SmithAlistair Smith

HSBC (Joint Global Coordinator and Joint Bookrunner to Elementis)Mark Dickenson +44 (0) 207 991 8888Sam Barnett

Evercore (Financial Advisor to Elementis)Tom Massey +44 (0) 207 046 6741Kirtan Pansari

OGG Consulting (Transaction consultant)Oli Greaves +44 (0) 7795 505 663 

Important Notices

This announcement has been issued by and is the sole responsibility of the Company. This announcement is not a circular or a prospectus but an advertisement and investors should not acquire any Nil Paid Rights, Fully Paid Rights or New Ordinary Shares referred to in this announcement except on the basis of the information contained in the Circular and the Prospectus published by the Company in connection with the Acquisition and the Rights Issue. The information contained in this announcement is for background purposes only and does not purport to be full or complete. The information in this announcement is subject to change. Copies of the Circular and the Prospectus are available from the registered office of the Company and on the Company's website, www.elementisplc.com, provided that the Circular and the Prospectus are not, subject to certain exceptions, be available to certain Shareholders in certain restricted or Excluded Territories. The Circular and the Prospectus give further details of the Acquisition and the Rights Issue.

This announcement is for information purposes only and is not intended to and does not constitute or form part of any offer to sell or issue, or any solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities in the United States or any other jurisdiction. The information contained in this announcement is not for release, publication or distribution to persons in, and should not be distributed, forwarded to or transmitted in or into, the United States, Australia, Canada, Japan, South Africa or any other jurisdiction where to do so might constitute a violation of local securities laws or regulations.

The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under the securities legislation of any state or other jurisdiction of the United States or under the applicable securities laws of Australia, Canada, Japan or South Africa. The securities referred to herein may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There has been and will be no public offering of the securities referred to herein in the United States.

The distribution of this announcement into jurisdictions other than the United Kingdom may be restricted by law, and, therefore, persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws of such jurisdiction. In particular, this announcement, the Circular and Prospectus (once published) and the provisional allotment letters (once printed) should not, subject to certain exceptions, be distributed, forwarded to or transmitted in or into the United States, Australia, Canada, Japan, South Africa or any other restricted or excluded territories or any jurisdiction where to do so would be unlawful.

This announcement does not constitute a recommendation concerning any investor's decision or options with respect to the Acquisition or the Rights Issue. The price and value of securities can go down as well as up. Past performance is not a guide to future performance. The contents of this announcement are not to be construed as legal, business, financial or tax advice. Each shareholder or prospective investor should consult his, her or its own independent legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.

UBS Limited and HSBC Bank plc (together, the "Underwriters"), each of which is authorised by the Prudential Regulation Authority (the "PRA") and regulated in the United Kingdom by the PRA and the Financial Conduct Authority (the "FCA"), are each acting for the Company and for no one else in connection with the Acquisition and the Rights Issue, and will not regard any other person as a client in relation to the Acquisition and the Rights Issue and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in connection with the Acquisition, the Rights Issue or any other matter, transaction or arrangement referred to in this announcement.

Apart from the responsibilities and liabilities, if any, which may be imposed on the Underwriters by the FSMA or the regulatory regime established thereunder, neither of the Underwriters nor any of their respective affiliates accepts any responsibility or liability whatsoever and makes no representation or warranty, express or implied, for the contents of this announcement, including its accuracy, fairness, sufficiency, completeness or verification or for any other statement made or purported to be made by it, or on its behalf, in connection with the Company or the Acquisition or the Rights Issue and nothing in this announcement is, or shall be relied upon as, a promise or representation in this respect, whether as to the past or future. Each of the Underwriters and their respective affiliates accordingly disclaims to the fullest extent permitted by law all and any responsibility and liability whether arising in tort, contract or otherwise (save as referred to above) which it might otherwise have in respect of this announcement or any such statement. Furthermore, each of the Underwriters and/or their affiliates provides various investment banking, commercial banking and financial advisory services from time to time to the Company.

No person has been authorised to give any information or to make any representations other than those contained in this announcement and the Circular and Prospectus and, if given or made, such information or representations must not be relied on as having been authorised by the Company, UBS or HSBC. Subject to the Listing Rules, the Prospectus Rules and the Disclosure Guidance and Transparency Rules of the FCA, the issue of this announcement shall not, in any circumstances, create any implication that there has been no change in the affairs of the Company since the date of this announcement or that the information in it is correct as at any subsequent date.

Each of the Underwriters and/or their respective affiliates, acting as investors for their own accounts, may, in accordance with applicable legal and regulatory provisions, engage in transactions in relation to the Nil Paid Rights, the Fully Paid Rights, the New Ordinary Shares and/or related instruments for their own account for the purpose of hedging their underwriting exposure or otherwise. Except as required by applicable law or regulation, the Underwriters and their respective affiliates do not propose to make any public disclosure in relation to such transactions.

This announcement contains certain forecasts, projections and other forward-looking statements (i.e., all statements other than statements of historical fact) in relation to, or in respect of the financial condition, operations or businesses of the Group and/or Mondo. Statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. Any such statements involve risk and uncertainty because they relate to future events and circumstances and are based on current assumptions and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. There are many factors that could cause actual results or developments to differ materially from those expressed or implied by any such forward looking statements, including, but not limited to, matters of a political, economic, business, competitive or reputational nature. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No statement in this announcement should be construed as a profit estimate or profit forecast. Neither the Company nor any other person undertakes any obligation to update or revise any forward looking statement to reflect any change in circumstances or expectations.

Information to Distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares have been subject to a product approval process, which has determined that they each are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares may decline and investors could lose all or part of their investment; the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares offer no guaranteed income and no capital protection; and an investment in the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offer. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Underwriters will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares and determining appropriate distribution channels.

Date   Source Headline
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.